Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - adrenaline (epinephrine) acid tartrate, quantity: 18.2 microgram/ml (equivalent: adrenaline (epinephrine), qty 10 microgram/ml); lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide; sodium metabisulfite - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu - powder for injection - 18 miu - active: interferon alfa-2a 18 miu excipient: albumin sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu/ml;   - solution for injection - 9miu/0.5ml - active: interferon alfa-2a 18 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa;  ; entacapone 200mg; levodopa 75mg - film coated tablet - 75mg/18.75mg/200mg - active: carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa   entacapone 200mg levodopa 75mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

leo laboratories limited - tinzaparin sodium - solution for injection - 18,000 iu in 0.9 ml international unit(s)/millilitre - heparin group; tinzaparin

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - tiotropium bromide - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

European Union - English - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.